Value in Health Regional Issues

Value in Health Regional Issues is an open access journal that Elsevier publishes for ISPOR, the Professional Society for Health Economics and Outcomes Research, carrying health economics and outcomes research from Africa, Asia, Europe, Latin America and other world regions. The 2025 Journal Citation Reports place it in the third quartile of two health-services categories with an impact factor of 1.9.《健康价值区域研究》是 Elsevier 为 ISPOR（Professional Society for Health Economics and Outcomes Research）出版的开放获取期刊，刊载非洲、亚洲、欧洲与拉丁美洲等区域的卫生经济学及结果研究成果，2025 年版期刊引证报告给出的影响因子为 1.9，在两个卫生服务类目中处于 Q3 区。

Scope

• Every submission is read against a regional frame, so authors are asked to name the country or the group of countries whose decision makers the analysis is meant to inform, instead of leaving the setting implicit.每篇来稿都按区域视角衡量，作者须写明分析服务于哪个国家或哪组国家的决策者，不把研究场景留给读者去猜。
• Cost-effectiveness, cost-utility, cost-benefit and cost-minimisation analyses form the working core, and budget impact modelling appears beside them where payers need an affordability view rather than a ratio.成本效果分析与成本效用分析构成主干，成本效益与成本最小化两型并列其侧，支付方需要可负担性判断时，预算影响模型也会同时出现。
• Health technology assessment is treated as institutional practice as well as method, with papers on appraisal committees, priority-setting exercises, managed entry agreements and the evidence packs that agencies actually receive.卫生技术评估既被当作方法，也被当作制度实践，文章涉及评审委员会与优先级设定，也涉及风险分担准入协议以及机构实际收到的证据包。
• Reimbursement and pricing questions recur, covering coverage lists, reference pricing, tendering for generics, risk-sharing contracts and the negotiation routes that decide whether a product reaches patients at all.报销与定价问题反复出现，涉及报销目录与参考定价，也涉及仿制药招标与风险分担合约，以及决定产品能否到达患者的谈判路径。
• Patient-reported outcomes occupy a large share of the pages, running from translation and cross-cultural adaptation of instruments to psychometric testing in populations for which the original validation sample does not apply.患者报告结局占据不少篇幅，从量表的翻译与跨文化调适，到在原始验证样本不适用的群体里重做心理测量学检验。
• Utility measurement follows the same regional logic, with EQ-5D value sets elicited for individual countries, comparisons of national scoring tariffs, and mapping studies that convert disease-specific scores into utilities.效用测量沿同一套区域逻辑展开，文章为单个国家测算 EQ-5D 值集，比较各国积分体系，也做把疾病专属得分换算成效用的映射研究。
• Costing work covers cost-of-illness estimates, unit cost derivation from hospital accounts, patient-level collection of resource use, and the informal payments that official tariffs leave out of the bill.成本测算涵盖疾病经济负担估算与单位成本推导，也包括患者层面的资源使用采集，以及官方价格表未计入的非正式支付。
• Epidemiological inputs to models also belong here, including registry and claims analyses, prevalence estimates for small populations, and real-world evidence assembled from local health information systems.模型的流行病学输入同样在范围内，包括登记库与理赔数据分析、小人群的患病率估计，以及从本地卫生信息系统汇总的真实世界证据。
• Financing and coverage design draw steady submissions on social health insurance, tax-funded schemes, voluntary prepayment, out-of-pocket spending and the catastrophic expenditure that follows a serious illness.筹资与保障设计来稿稳定，社会医疗保险与税收筹资两类制度最常出现，自愿预付与自付支出次之，重病之后的灾难性卫生支出也常有专文。
• Equity and access studies examine who is left outside a benefit package, how rural and urban utilisation diverge, and what informal charges do to the effective cost of care.公平与可及研究关注谁被挡在保障包之外，城乡服务利用如何分化，以及非正式收费怎样抬高实际就医成本。
• Pharmaceutical and vaccine economics appear often, covering the uptake of generics and biosimilars, procurement prices, the value of vaccination programmes and the affordability of newer antimicrobial or oncology agents.药品与疫苗经济学出现频繁，涵盖仿制药与生物类似药的采用与采购价格，也涵盖疫苗接种规划的价值与新型抗菌药或肿瘤药的可负担性。
• Methodological papers address transferability, discount rates, cost-effectiveness thresholds and the adaptation of models built elsewhere, questions that surface whenever a jurisdiction borrows an analysis from abroad.方法学文章处理可移植性与贴现率，也处理成本效果阈值和异地模型的改造，这些题目在任何辖区借用他国分析时都会出现。
• Work on teaching and on building health economics capacity also finds a place, tied to the training, mentoring and consensus exercises run through ISPOR's regional chapters and networks.教学与能力建设类文章同样有位置，对应 ISPOR 各区域分会及网络开展的培训、导师项目与共识工作。
• Article types run from original research and methodological papers to policy analyses, structured reviews and short communications, each with its own length limit and abstract rules.稿件类型从原创研究与方法学论文，延伸到政策分析、结构化综述与短篇通讯，每类各有篇幅与摘要规定。

History

• ISPOR, the Professional Society for Health Economics and Outcomes Research, launched the title in 2012 as a regional companion to Value in Health, the society's general journal founded in 1998.ISPOR（Professional Society for Health Economics and Outcomes Research）于 2012 年创办本刊，作为学会综合刊 Value in Health 的区域姊妹刊，后者创于 1998 年。
• The society presents the journal as its outlet for regional advancement in health economics and outcomes research, a remit that sits beside the worldwide scope of the parent title.学会把本刊称作推进区域卫生经济学与结果研究的阵地，这一任务与主刊的全球覆盖并行。
• Volume 1 opened in May 2012, a second issue followed that December, and 2013 carried three issues dated May, September and December.第 1 卷于 2012 年 5 月开局，同年 12 月出第 2 期，2013 年则排出 5 月、9 月与 12 月三期。
• Issue numbering inside a volume was dropped after those early years, and from the mid-2010s the journal has published as a run of separately numbered volumes whose articles carry electronic article numbers instead of page ranges.早期几卷之后，卷内分期编号被取消，2010 年代中期起刊物以连续出版的形态一卷接一卷推出，文章使用电子文章编号而非起止页码。
• Crossref deposits list six volumes for each year from 2022 onward, running from volumes 27 to 32 in 2022 and from 45 to 50 in 2025, with roughly a hundred articles spread over that run.Crossref 存缴显示 2022 年以来每年固定 6 卷，2022 年为第 27 至 32 卷，2025 年为第 45 至 50 卷，每年约一百篇文章分布在这串卷次里。
• Elsevier publishes the journal from New York, and the National Library of Medicine's imprint record shows no change of publisher since the first volume.出版方 Elsevier 以纽约为出版地，国家医学图书馆的出版者记录自首卷起未见转手。
• One identifier, 2212-1099, serves the printed and the electronic form alike, so catalogues and link resolvers arrive at the same record from either version.该刊只用一个刊号 2212-1099，纸本与电子版共用，目录与链接解析器从任一形态都落到同一条记录。
• MEDLINE and PubMed took the journal from volume 9 in May 2016, and citations from the earlier volumes remain there on a selective basis only.MEDLINE 与 PubMed 自 2016 年 5 月第 9 卷起收录本刊，此前各卷仅有选择性引用进入 PubMed。
• Clarivate lists the title in the Emerging Sources Citation Index, which brought it into the Journal Citation Reports and produced a first impact factor in the 2023 edition.科睿唯安把本刊收入 Emerging Sources Citation Index，刊物由此进入期刊引证报告，并在 2023 年版拿到首个影响因子。
• The impact factor moved from 1.4 for 2023 to 1.5 for 2024 and 1.9 for 2025, against a five-year figure of 2.2 and a Journal Citation Indicator of 0.57.影响因子从 2023 年的 1.4 升到 2024 年的 1.5，2025 年为 1.9，5 年数值 2.2，期刊引用指标 0.57。
• Placement is third quartile in both categories, 128th of 194 titles in HEALTH CARE SCIENCES & SERVICES and 85th of 125 in HEALTH POLICY & SERVICES.两个类目都排在 Q3 区，HEALTH CARE SCIENCES & SERVICES 为 194 种刊物中的第 128 位，HEALTH POLICY & SERVICES 为 125 种中的第 85 位。
• The 2025 edition credits 1587 citations, about 102 articles a year and a cited half-life of 4.8 years, numbers that belong to a young and still small literature.2025 年版记录被引 1587 次，年发文约 102 篇，被引半衰期 4.8 年，这组数字对应一份年轻而体量有限的文献。
• The journal is listed in the Directory of Open Access Journals, and the 2025 reports record a gold open access share of roughly 26 percent of its output.该刊列入开放获取期刊名录（Directory of Open Access Journals），2025 年版报告记录的黄金开放获取比例为 26% 左右。

Editors

• Editorial responsibility rests with ISPOR, which appoints the editors of its journals, while Elsevier runs production, hosting and the online submission system.编辑职责归 ISPOR，学会任命旗下各刊的编辑，Elsevier 负责制作、托管与在线投稿系统。
• The current editor, the associate editors and the editorial board are listed on the journal's page at Elsevier, the authoritative roster for the title.现任主编、副编辑与编委会名单公布在 Elsevier 的刊物页面上，该页面即这份刊物的权威名录。
• Because the remit is regional, appointments are meant to cover the regions the journal serves, and the board draws on health economists, assessment analysts and payer advisers working across several continents.刊物面向区域，编辑人选相应覆盖所服务的各个地区，编委会由来自数个大洲的卫生经济学家、评估分析师与支付方顾问组成。
• Review follows the publisher's standard sequence, beginning with an editorial assessment that can return a manuscript without external referees and, for those that pass, calls for independent reports.评审沿用出版方的标准流程，先由编辑初评，可以直接退稿而不送外审，通过初评的稿件通常取得两份独立审稿意见。
• Referees are drawn from the society's membership and from the agencies, universities and firms where those members work, which keeps the pool close to the settings the papers describe.审稿人从学会会员中约请，也来自会员任职的机构、大学与企业，审稿队伍因此贴近论文所描述的现实场景。
• Handling editors weigh regional relevance alongside technical quality, so a technically sound analysis with no bearing on a local decision problem may be redirected to the parent journal or declined.承办编辑在技术质量之外还看区域相关性，一份方法可靠却与本地决策问题无关的分析，可能被转给主刊或退回。
• Authors must justify the choice of perspective, the source of unit costs, and the currency and price year of the resources they costed, since comparability across countries rests on those details.作者须说明研究视角的选择、单位成本的来源，以及价格所用的币种与年份，跨国可比性正建立在这些细节上。
• Contents are organised around economic evaluation, health policy, patient-reported outcomes and regional perspectives, and manuscripts go to the editors who work in the matching area.刊物按经济学评价与卫生政策两类主题组织内容，患者报告结局与区域视角同样分列，来稿交由相应领域的编辑处理。
• Commentaries and policy pieces usually arrive by invitation or after a short proposal to the editorial office, while research articles take the ordinary submission route.评论与政策短文多由编辑部邀约，或以简短选题说明进入流程，研究论文走常规投稿通道。
• Accepted manuscripts are posted article by article as production clears them, so no author waits for a volume to close and the citation details appear with the article number.录用稿件在制作完成后逐篇上线，作者无需等一卷凑齐，引用信息随文章编号一同给出。